Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients

Oncotarget

Volumn 5, Issue 3, 2014, Pages 824-840

  Singh, Prashant K ^a   Preus, Leah ^a   Hu, Qiang ^a   Yan, Li ^a   Long, Mark D ^a   Morrison, Carl D ^a   Nesline, Mary ^a   Johnson, Candace S ^a   Koochekpour, Shahriar ^a   Kohli, Manish ^b   Liu, Song ^a   Trump, Donald L ^a   Sucheston Campbell, Lara E ^a   Campbell, Moray J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Biochemical progression; Cancer epigenetics; MicroRNA; MiR 103; MiR 125b; MiR 222; Prostate cancer

Indexed keywords

MICRORNA; MICRORNA 103; MICRORNA 125B; MICRORNA 222; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DECISION MAKING; HUMAN; MALE; MICROARRAY ANALYSIS; NON INVASIVE PROCEDURE; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; TREATMENT FAILURE; BIOSYNTHESIS; BLOOD; DISEASE COURSE; EPIGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

CELL LINE, TUMOR; DISEASE PROGRESSION; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 84896807570     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1776     Document Type: Article

References (88)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-1328.
2. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-1319.
3. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, Nishiura T, Murphy GP and Chu TM. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer research. 1980; 40(12):4658-4662.
4. Wang MC, Valenzuela LA, Murphy GP and Chu TM. Purification of a human prostate specific antigen. Investigative urology. 1979; 17(2):159-163.
5. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB and Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. The Journal of urology. 2007; 177(2):540-545.
6. Freedland SJ. Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer. 2011; 117(6):1123-1135.
7. Buyyounouski MK, Pickles T, Kestin LL, Allison R and Williams SG. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(15):1857-1863.
8. Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD and Chi KN. Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. International journal of molecular sciences. 2013; 14(4):7757-7770.
9. Tsuchiyama K, Ito H, Taga M, Naganuma S, Oshinoya Y, Nagano K, Yokoyama O and Itoh H. Expression of MicroRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer. The Prostate. 2013; 73(8):827-834.
10. Sun D, Layer R, Mueller AC, Cichewicz MA, Negishi M, Paschal BM and Dutta A. Regulation of several androgeninduced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells. Oncogene. 2013.
11. Sita-Lumsden A, Dart DA, Waxman J and Bevan CL. Circulating microRNAs as potential new biomarkers for prostate cancer. British journal of cancer. 2013; 108(10):1925-1930.
12. Selth LA, Townley SL, Gillis JL, Tilley WD and Butler LM. Identification of Prostate Cancer-Associated MicroRNAs in Circulation Using a Mouse Model of Disease. Methods in molecular biology. 2013; 1024:235-246.
13. Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM and Tilley WD. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British journal of cancer. 2013; 109(3):641-650.
14. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ and Thibodeau SN. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer research. 2009; 69(24):9490-9497.
15. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J and Nemunaitis J. MicroRNA profile analysis of human prostate cancers. Cancer gene therapy. 2009; 16(3):206-216.
16. Siva AC, Nelson LJ, Fleischer CL, Majlessi M, Becker MM, Vessella RL and Reynolds MA. Molecular assays for the detection of microRNAs in prostate cancer. Molecular cancer. 2009; 8:17.
17. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(30):10513-10518.
18. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM and Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer research. 2008; 68(15):6162-6170.
19. Lussier YA, Stadler WM and Chen JL. Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures. Journal of the American Medical Informatics Association: JAMIA. 2012; 19(2):156-160.
20. Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS and Kantoff PW. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate. 2012.
21. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30):10513-10518.
22. Selth LA, Tilley WD and Butler LM. Circulating microRNAs-macro-utility as markers of prostate cancer? Endocr Relat Cancer. 2012.
23. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee TJ, Hebert FE, Kao YS, Skinner J and Rayford W. Establishment and characterization of a primary androgenresponsive African-American prostate cancer cell line, E006AA. Prostate. 2004; 60(2):141-152.
24. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC and Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997; 3(12 Pt 1):2493-2500.
25. Ambrosone CB. Sample collection, processing, and storage for large-scale studies: biorepositories to support cancer research. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006; 15(9):1574.
26. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F and Vandesompele J. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10(6):R64.
27. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3(R3).
28. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22.
29. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M and Hatzigeorgiou AG. DIANA-mirPath: Integrating human and mouse microRNAs in pathways. Bioinformatics. 2009; 25(15):1991-1993.
30. Cox DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society. 1972; 34(2):187-220.
31. Friedman J, Hastie T and Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22.
32. Noah Simon JHF, Trevor Hastie, Rob Tibshirani. Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. Journal of Statistical Software. 2011; 39(5):1-13.
33. Bello D, Webber MM, Kleinman HK, Wartinger DD and Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus. 18. Carcinogenesis. 1997; 18(6):1215-1223.
34. Ling MT, Chan KW and Choo CK. Androgen induces differentiation of a human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line. J Endocrinol. 2001; 170(1):287-296.
35. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC and Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994; 54(10):2577-2581.
36. Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M and Gout PW. MicroRNAs associated with metastatic prostate cancer. PLoS ONE. 2011; 6(9):e24950.
37. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Camara-Lopes LH and Srougi M. MicroRNA expression profiles in the progression of prostate cancerfrom high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol. 2011.
38. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, Bangma CH, Litman T, Visakorpi T and Jenster G. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012; 31(8):978-991.
39. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010; 126(5):1166-1176.
40. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-2261.
41. Ozen M, Creighton CJ, Ozdemir M and Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008; 27(12):1788-1793.
42. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007; 67(13):6130-6135.
43. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R and Sultmann H. Circulating miRNAs are correlated with tumor progression in prostate cancer. International journal of cancer Journal international du cancer. 2011; 128(3):608-616.
44. Dai Y, Xie CH, Neis JP, Fan CY, Vural E and Spring PM. MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck. 2011; 33(6):786-791.
45. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, Martinez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D and Rodriguez-Antona C. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 2011; 18(1):85-95.
46. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS and Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010; 1(12):e105.
47. Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM and Anderson ML. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 2010; 70(5):1906-1915.
48. Valastyan S, Chang A, Benaich N, Reinhardt F and Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res. 2010; 70(12):5147-5154.
49. Bello-DeOcampo D and Tindall DJ. TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets. 2003; 4(3):197-207.
50. Huang K, Zhang JX, Han L, You YP, Jiang T, Pu PY and Kang CS. MicroRNA roles in beta-catenin pathway. Molecular cancer. 9:252.
51. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA, Goodall GJ and Kurie JM. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. The Journal of clinical investigation. 2011; 121(4):1373-1385.
52. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature cell biology. 2008; 10(5):593-601.
53. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011; 470(7333):269-273.
54. Thorne JL, Maguire O, Doig CL, Battaglia S, Fehr L, Sucheston LE, Heinaniemi M, O'Neill LP, McCabe CJ, Turner BM, Carlberg C and Campbell MJ. Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res. 2011; 39(6):2045-2056.
55. Singh PK, Campbell, M. J. The interaction of microRNA and epigenetic modifications in prostate cancer. Cancers. 2013; In Press.
56. Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM and Stein GS. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer research. 2008; 68(8):2773-2780.
57. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG and Ciafre SA. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One. 2008; 3(12):e4029.
58. Lin D, Cui F, Bu Q and Yan C. The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer. J Int Med Res. 2011; 39(5):1870-1875.
59. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J and Nemunaitis J. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 2009; 16(3):206-216.
60. Sun T, Wang Q, Balk S, Brown M, Lee GS and Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009; 69(8):3356-3363.
61. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, Dyrskjot L, Eltze E, Wieland W, Keck B, Ekici AB, Grasser F and Wullich B. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. International journal of cancer Journal international du cancer. 2012; 130(3):611-621.
62. Lee YS, Kim HK, Chung S, Kim KS and Dutta A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the downregulation of putative targets during differentiation. J Biol Chem. 2005; 280(17):16635-16641.
63. Yu D, Zhou H, Xun Q, Xu X, Ling J and Hu Y. microRNA-103 regulates the growth and invasion of endometrial cancer cells through the downregulation of tissue inhibitor of metalloproteinase 3. Oncol Lett. 2012; 3(6):1221-1226.
64. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM and Baffa R. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007; 25(5):387-392.
65. Martello G, Rosato A, Ferrari F, Manfrin A, Cordenonsi M, Dupont S, Enzo E, Guzzardo V, Rondina M, Spruce T, Parenti AR, Daidone MG, Bicciato S and Piccolo S. A MicroRNA targeting dicer for metastasis control. Cell. 2010; 141(7):1195-1207.
66. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S, Valtieri M, Calin GA, Liu CG, Sorrentino A, Croce CM and Peschle C. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A. 2005; 102(50):18081-18086.
67. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM and Farace MG. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005; 334(4):1351-1358.
68. Hao J, Zhang C, Zhang A, Wang K, Jia Z, Wang G, Han L, Kang C and Pu P. miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. Oncol Rep. 2012; 27(5):1504-1510.
69. Nikiforova MN, Tseng GC, Steward D, Diorio D and Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008; 93(5):1600-1608.
70. Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R, Elemento O and Fahey TJ, 3rd. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res. 2012; 18(7):2032-2038.
71. Li N, Tang B, Zhu ED, Li BS, Zhuang Y, Yu S, Lu DS, Zou QM, Xiao B and Mao XH. Increased miR-222 in H. pyloriassociated gastric cancer correlated with tumor progression by promoting cancer cell proliferation and targeting RECK. FEBS Lett. 2012; 586(6):722-728.
72. Wang J, Wang Q, Liu H, Hu B, Zhou W and Cheng Y. MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer Lett. 2010; 297(2):137-143.
73. Kim BH, Hong SW, Kim A, Choi SH and Yoon SO. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 2012.
74. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G and Voros D. Expression of MicroRNAs in Patients With Pancreatic Cancer and Its Prognostic Significance. Pancreas. 2012.
75. Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F and Sanchez-Carbayo M. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012; 180(5):1808-1815.
76. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D and Cheng JQ. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem. 2008; 283(45):31079-31086.
77. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S and Majumder S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008; 283(44):29897-29903.
78. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, Dyrskjot L, Eltze E, Wieland W, Keck B, Ekici AB, Grasser F and Wullich B. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. International journal of cancer Journal international du cancer. 2012; 130(3):611-621.
79. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK and Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nature reviews Clinical oncology. 2011; 8(8):467-477.
80. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ and deVere White RW. An androgenregulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007; 104(50):19983-19988.
81. Yang X, Bemis L, Su LJ, Gao D and Flaig TW. miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2. BioResearch open access. 2012; 1(2):55-62.
82. Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012; 181(5):1573-1584.
83. Palma J, Yaddanapudi SC, Pigati L, Havens MA, Jeong S, Weiner GA, Weimer KM, Stern B, Hastings ML and Duelli DM. MicroRNAs are exported from malignant cells in customized particles. Nucleic acids research. 2012; 40(18):9125-9138.
84. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, Hastings ML and Duelli DM. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One. 2010; 5(10):e13515.
85. Ignatiadis M and Desmedt C. Predicting risk of breast cancer recurrence using gene-expression profiling. Pharmacogenomics. 2007; 8(1):101-111.
86. Li Q, Seo JH, Stranger B, McKenna A, Pe'er I, Laframboise T, Brown M, Tyekucheva S and Freedman ML. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell. 2013; 152(3):633-641.
87. Batura D and Gopal Rao G. The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother. 2012.
88. Glaser AP, Novakovic K and Helfand BT. The Impact of Prostate Biopsy on Urinary Symptoms, Erectile Function, and Anxiety. Curr Urol Rep. 2012.